search
Back to results

Werewolf Flow 50 During ACL Reconstruction

Primary Purpose

Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Werewolf FLOW 50
Control
Sponsored by
Children's Hospital Colorado
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Anterior Cruciate Ligament Injuries focused on measuring ACL, Anterior Cruciate Ligament, Arthrofibrosis, Knee

Eligibility Criteria

12 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ages 12-18 (inclusive) at time of surgery
  • Scheduled to undergo ACL reconstruction performed at Children's Hospital Colorado or associated network of care site.

Exclusion Criteria:

  • Underlying congenital or musculoskeletal disorders
  • Pregnant females, prisoners, and wards of the state
  • Persons deemed incompetent and those who have limited decision-making capacity

Sites / Locations

  • Children's Hospital Colorado,Recruiting
  • Children's Hospital Colorado, Main CampusRecruiting
  • Children's Hospital Colorado, North CampusRecruiting
  • Children's Hospital Colorado, South CampusRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Werewolf FLOW 50 Group

Control Group

Arm Description

The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.

No electrocautery device will be used during surgical treatment for patients assigned to this group.

Outcomes

Primary Outcome Measures

Rates of Post-Operative Arthrofibrosis
Based on post-operative MRIs of the knee, we will compare the rates of post-operative arthrofibrosis between the Werewolf FLOW 50 Group and the Control Group.

Secondary Outcome Measures

Range of Motion
Based on post-operative clinical examinations, we will compare the knee range of motion between the Werewolf FLOW 50 Group and the Control Group.
Patient Reported Outcomes
Based on patient reported outcomes (patient surveys) completed pre-operatively and post-operatively, we will compare levels of pain, functionality, overall healing, and quality of life between the Werewolf FLOW 50 Group and the Control Group.
Complications
We will compare rates of post-operative complications between the Werewolf FLOW 50 Group and the Control Group.

Full Information

First Posted
June 1, 2021
Last Updated
May 18, 2023
Sponsor
Children's Hospital Colorado
Collaborators
Smith & Nephew, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04998656
Brief Title
Werewolf Flow 50 During ACL Reconstruction
Official Title
Werewolf Flow 50 During ACL Reconstruction: A Randomized Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 12, 2021 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Children's Hospital Colorado
Collaborators
Smith & Nephew, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to compare the outcomes, ease of use, and cost of the Werewolf FLOW50 device to the institutional standard of care which is does not include the use of electrocautery devices during anterior cruciate ligament reconstruction (ACLR) surgery in patients 12-18 years of age using a randomized control trial design. The investigators hypothesize that a lower proportion of participants who undergo ACLR and are randomized to the Werewolf FLOW50 procedure will experience post-operative arthrofibrosis compared to those randomized to standard of care (control group).
Detailed Description
The investigators foresee minimal risks to participants. The Werewolf FLOW50 is an FDA approved medical device to be used in the knee joint. he surgeon performing each surgery has used both the Werewolf FLOW50 device (according to FDA-approved indications for use) and no electrocautery device as standard of care during ACL reconstruction surgery. There is minimal risk associated with the subsequent MRI. Participants may experience slight discomfort from the confined space, flashing lights in their eyes, or temporary warmth/reddening of the skin following MRI. Participants will be informed of these risks and discomforts and pregnant participants or those with any metal and/or electronic devices inside their bodies will not receive the MRI. There is the risk of unintended disclosure of protected health information (PHI) to individuals outside the research team. To mitigate this risk, data points are entered into a password-protected, HIPAA compliant REDCap database accessible to only the PIs and study personnel. Children's Colorado affiliated and approved study personal will have access to all study information collected at all involved study sites. However, other study sites will only have access to the information collected on patients enrolled at their site. We believe this system will contribute to the protection of PHI. The only PHI collected will be visit dates; all participants will be linked to their information via a unique study identifier. The PI will periodically review the status of this protocol. Any unanticipated problems will be disclosed to COMIRB [Colorado Multiple Institutional Review Board] within five days with a cover letter detailing the assessment and actions to be taken.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear, Arthrofibrosis of Knee
Keywords
ACL, Anterior Cruciate Ligament, Arthrofibrosis, Knee

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Participants will not be told whether the Werewolf Flow 50 device was used during their surgery or not.
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Werewolf FLOW 50 Group
Arm Type
Active Comparator
Arm Description
The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Description
No electrocautery device will be used during surgical treatment for patients assigned to this group.
Intervention Type
Device
Intervention Name(s)
Werewolf FLOW 50
Intervention Description
Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
Intervention Type
Other
Intervention Name(s)
Control
Other Intervention Name(s)
No Electrocautery Device
Intervention Description
Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
Primary Outcome Measure Information:
Title
Rates of Post-Operative Arthrofibrosis
Description
Based on post-operative MRIs of the knee, we will compare the rates of post-operative arthrofibrosis between the Werewolf FLOW 50 Group and the Control Group.
Time Frame
1 year post-operative
Secondary Outcome Measure Information:
Title
Range of Motion
Description
Based on post-operative clinical examinations, we will compare the knee range of motion between the Werewolf FLOW 50 Group and the Control Group.
Time Frame
1 year post-operative
Title
Patient Reported Outcomes
Description
Based on patient reported outcomes (patient surveys) completed pre-operatively and post-operatively, we will compare levels of pain, functionality, overall healing, and quality of life between the Werewolf FLOW 50 Group and the Control Group.
Time Frame
1 year post-operative
Title
Complications
Description
We will compare rates of post-operative complications between the Werewolf FLOW 50 Group and the Control Group.
Time Frame
1 year post-operative
Other Pre-specified Outcome Measures:
Title
Procedure Time
Description
After reviewing the operative note in each participant's medical record, we will compare the length of ACL reconstruction procedures between the Werewolf FLOW 50 Group and the Control Group.
Time Frame
Through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 12-18 (inclusive) at time of surgery Scheduled to undergo ACL reconstruction performed at Children's Hospital Colorado or associated network of care site. Exclusion Criteria: Underlying congenital or musculoskeletal disorders Pregnant females, prisoners, and wards of the state Persons deemed incompetent and those who have limited decision-making capacity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hannah C Rossing
Phone
720-434-2244
Email
hannah.rossing@childrenscolorado.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jay C Albright, MD
Organizational Affiliation
Children's Hospital Colorado
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital Colorado,
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80011
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Rossign
Phone
720-434-2244
Email
hannah.rossing@childrenscolorado.org
Facility Name
Children's Hospital Colorado, Main Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Rossing
Phone
720-434-2244
Email
hannah.rossing@childrenscolorado.org
Facility Name
Children's Hospital Colorado, North Campus
City
Broomfield
State/Province
Colorado
ZIP/Postal Code
80023
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Rossing
Phone
720-434-2244
Email
hannah.rossing@childrenscolorado.org
Facility Name
Children's Hospital Colorado, South Campus
City
Highlands Ranch
State/Province
Colorado
ZIP/Postal Code
80129
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Rossing, BA
Phone
720-434-2244
Email
hannah.rossing@childrenscolorado.org

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will not be shared with individuals outside of the authorized study team.
Links:
URL
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K162074
Description
510(k) Premarket Notification for Werewolf FLOW 50 Device

Learn more about this trial

Werewolf Flow 50 During ACL Reconstruction

We'll reach out to this number within 24 hrs